Your browser doesn't support javascript.
loading
ALSUntangled # 69: astaxanthin.
Fullam, Timothy; Armon, Carmel; Barkhaus, Paul; Barnes, Benjamin; Beauchamp, Morgan; Benatar, Michael; Bertorini, Tulio; Bowser, Robert; Bromberg, Mark; Mascias Cadavid, Javier; Carter, Gregory T; Dimachkie, Mazen; Ennist, Dave; Feldman, Eva L; Heiman-Patterson, Terry; Jhooty, Sartaj; Lund, Isaac; Mcdermott, Christopher; Pattee, Gary; Ratner, Dylan; Wicks, Paul; Bedlack, Richard.
Afiliación
  • Fullam T; Department of Neurology, UTSA, San Antonio, TX, USA.
  • Armon C; Department of Neurology, Loma Linda University, Loma Linda, CA, USA.
  • Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Barnes B; Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
  • Beauchamp M; Neurosciences Clinical Trials Unit, UNC Chapel Hill, NC, USA.
  • Benatar M; Department of Neurology, University of Miami, Miami, FL, USA.
  • Bertorini T; Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Bowser R; Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA.
  • Mascias Cadavid J; ALS Department, Hospital Carlos III-La Paz, Madrid, Spain.
  • Carter GT; Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
  • Dimachkie M; Department of Neurology, University of Kansas, Kansas City, KS, USA.
  • Ennist D; Origent Data Sciences, Inc, Vienna, VA, USA.
  • Feldman EL; Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  • Heiman-Patterson T; Department of Neurology, Temple Health, Philadelphia, PA, USA.
  • Jhooty S; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Lund I; Green Hope High School, Cary, NC, USA.
  • Mcdermott C; Department of Neuroscience, University of Sheffield, Sheffield, UK.
  • Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Ratner D; Tulane University, New Orleans, LA, USA.
  • Wicks P; Independent Consultant, Lichfield, UK, and.
  • Bedlack R; Department of Neurology, Duke University, Durham, NC, USA.
Amyotroph Lateral Scler Frontotemporal Degener ; 24(5-6): 553-557, 2023 08.
Article en En | MEDLINE | ID: mdl-36694292
ABSTRACT
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified "ALS reversal" occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Terapias Complementarias / Esclerosis Amiotrófica Lateral Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Terapias Complementarias / Esclerosis Amiotrófica Lateral Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos